Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

54.65 +0.67 (+1.24%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,059,495
Open	54.41
Bid (Size)	53.10 (100)
Ask (Size)	56.98 (100)
Prev. Close	53.98
Today's Range	53.17 - 56.24
52wk Range	27.66 - 76.61
Shares Outstanding	93,706,790
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 18, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the...

Via MarketMinute

Performance

YTD	+17.6%	+17.6%
1 Month	+2.5%	+2.5%
3 Month	+25.0%	+25.0%
6 Month	+67.7%	+67.7%
1 Year	-28.2%	-28.2%

More News

Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗

February 24, 2026

Via Chartmill

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 24, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

February 11, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

February 10, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 05, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 02, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Pricing of $550 Million Public Offering

January 29, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 29, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

January 22, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte's Chief Technical Ops Officer Sells Shares ↗

January 03, 2026

Via The Motley Fool

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

December 08, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗

November 18, 2025

Via MarketBeat

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

November 04, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗

September 30, 2025

Via Benzinga

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

September 30, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗

September 11, 2025

Via Benzinga

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

September 03, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

Vaxcyte (PCVX) Q2 Loss Widens 11% ↗

August 06, 2025

Via The Motley Fool

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

August 06, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 01, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 01, 2025

Via Benzinga

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?

Yes, Vaxcyte, Inc. - Common Stock is publicly traded.

What exchange does Vaxcyte, Inc. - Common Stock trade on?

Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vaxcyte, Inc. - Common Stock?

The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market

What is the current price of Vaxcyte, Inc. - Common Stock?

The current price of Vaxcyte, Inc. - Common Stock is 54.65

When was Vaxcyte, Inc. - Common Stock last traded?

The last trade of Vaxcyte, Inc. - Common Stock was at 03/20/26 04:00 PM ET

What is the market capitalization of Vaxcyte, Inc. - Common Stock?

The market capitalization of Vaxcyte, Inc. - Common Stock is 5.12B

How many shares of Vaxcyte, Inc. - Common Stock are outstanding?

Vaxcyte, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.